NCT04979130View on ClinicalTrials.gov

Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)

PHASE4CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

October 16, 2024

Study Completion Date

October 16, 2024

Conditions
Type 2 DiabetesChronic InflammationIntestinal Permeability
Interventions
DRUG

Semaglutide

Semaglutide 1.34 mg/mL solution for injection in 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.

DRUG

Placebo

Semaglutide placebo, solution for injection, 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.

Trial Locations (1)

80045

University of Colorado Anschutz, Aurora

Sponsors

Collaborators (1)

Novo Nordisk A/S
All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

University of Colorado, Denver

OTHER